CD40LG and synovial sarcoma: In conclusion, despite the rather extensive literature supporting CD40 as a therapeutic target in autoimmune diseases, our study shows no clinical benefit of interfering with the CD40-CD154 interaction by expression of soluble CD40 fusion proteins at the levels of expression we were able to achieve in the SG in this animal model of SS.